JP2022515144A - オフザシェルフのダブルネガティブｔ細胞の産生および治療的使用 - Google Patents

オフザシェルフのダブルネガティブｔ細胞の産生および治療的使用 Download PDF

Info

Publication number
JP2022515144A
JP2022515144A JP2021535618A JP2021535618A JP2022515144A JP 2022515144 A JP2022515144 A JP 2022515144A JP 2021535618 A JP2021535618 A JP 2021535618A JP 2021535618 A JP2021535618 A JP 2021535618A JP 2022515144 A JP2022515144 A JP 2022515144A
Authority
JP
Japan
Prior art keywords
dnt
population
cells
expanded
allogeneic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021535618A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022515144A5 (https=
Inventor
リー チャン
ジョン ボク イ
ヒョンジョン カン
Original Assignee
ユニバーシティー ヘルス ネットワーク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティー ヘルス ネットワーク filed Critical ユニバーシティー ヘルス ネットワーク
Publication of JP2022515144A publication Critical patent/JP2022515144A/ja
Publication of JP2022515144A5 publication Critical patent/JP2022515144A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/92—Medium free of human- or animal-derived components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021535618A 2018-12-19 2019-12-19 オフザシェルフのダブルネガティブｔ細胞の産生および治療的使用 Pending JP2022515144A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782005P 2018-12-19 2018-12-19
US62/782,005 2018-12-19
PCT/CA2019/051866 WO2020124248A1 (en) 2018-12-19 2019-12-19 Production and therapeutic use of off-the-shelf double negative t cells

Publications (2)

Publication Number Publication Date
JP2022515144A true JP2022515144A (ja) 2022-02-17
JP2022515144A5 JP2022515144A5 (https=) 2022-12-20

Family

ID=71099979

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021535618A Pending JP2022515144A (ja) 2018-12-19 2019-12-19 オフザシェルフのダブルネガティブｔ細胞の産生および治療的使用

Country Status (6)

Country Link
US (2) US20220073877A1 (https=)
EP (1) EP3898950A4 (https=)
JP (1) JP2022515144A (https=)
CN (1) CN113454209A (https=)
CA (1) CA3123467A1 (https=)
WO (1) WO2020124248A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102394512B1 (ko) * 2021-05-03 2022-05-06 주식회사 지씨셀 동결 활성화 림프구 및 이의 제조 방법
EP4458378A4 (en) * 2021-12-30 2025-07-09 Chongqing Prec Biotech Co Ltd TECHNIQUE FOR PREPARING A UNIVERSAL CAR-T CELL, AND APPLICATION OF A UNIVERSAL CAR-T CELL
JP2025517437A (ja) * 2022-05-20 2025-06-05 武田薬品工業株式会社 操作された免疫細胞を産生する方法
CN117860782B (zh) * 2024-03-11 2024-05-28 中国康复科学所(中国残联残疾预防与控制研究中心) 双阴性t细胞在制备治疗脊髓损伤的药物中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056854A1 (en) * 2005-11-18 2007-05-24 University Health Network Method of expanding double negative t cells
CN104109653A (zh) * 2014-06-12 2014-10-22 浙江瑞顺生物技术有限公司 利用无动物血清培养体系大规模扩增人外周血dnt细胞的方法
JP2017527551A (ja) * 2014-08-15 2017-09-21 ユニバーシティ・ヘルス・ネットワーク がん治療のための免疫療法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953576B2 (en) * 2000-08-21 2005-10-11 University Health Network Method of modulating tumor immunity
RU2739770C2 (ru) * 2014-06-11 2020-12-28 полибайосепт ГмбХ Экспансия лимфоцитов с использованием композиции цитокинов для активной клеточной иммунотерапии
US11534460B2 (en) * 2015-05-11 2022-12-27 University Health Network Method for expansion of double negative regulatory T cells
US10201572B2 (en) * 2015-09-15 2019-02-12 University Health Network Combination therapy with double negative T-cells
CN105483083B (zh) * 2016-01-20 2018-10-23 北京医明佳和生物科技有限公司 双阴性t细胞的转化扩增方法
WO2019145956A1 (en) * 2018-01-25 2019-08-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods for improved immunotherapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056854A1 (en) * 2005-11-18 2007-05-24 University Health Network Method of expanding double negative t cells
CN104109653A (zh) * 2014-06-12 2014-10-22 浙江瑞顺生物技术有限公司 利用无动物血清培养体系大规模扩增人外周血dnt细胞的方法
JP2017527551A (ja) * 2014-08-15 2017-09-21 ユニバーシティ・ヘルス・ネットワーク がん治療のための免疫療法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MIN, B ET AL.: "Optimization of large-scale expansion and cryopreservation of human natural killer cells for anti-tu", IMMUNE NETW, vol. 18(4), JPN6023051878, 21 August 2018 (2018-08-21), pages 31, ISSN: 0005566129 *

Also Published As

Publication number Publication date
US20220073877A1 (en) 2022-03-10
WO2020124248A1 (en) 2020-06-25
US20250235482A1 (en) 2025-07-24
EP3898950A1 (en) 2021-10-27
EP3898950A4 (en) 2022-10-05
CA3123467A1 (en) 2020-06-25
CN113454209A (zh) 2021-09-28

Similar Documents

Publication Publication Date Title
Lee et al. Haploidentical natural killer cells infused before allogeneic stem cell transplantation for myeloid malignancies: a phase I trial
Childs et al. Bringing natural killer cells to the clinic: ex vivo manipulation
Lee et al. Developing allogeneic double-negative T cells as a novel off-the-shelf adoptive cellular therapy for cancer
Pittari et al. Revving up natural killer cells and cytokine-induced killer cells against hematological malignancies
Friedman et al. Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes
ES2771248T3 (es) Diferenciación de células NK ex vivo de células hematopoyéticas CD34+
JP2020141671A (ja) 改変された造血幹／前駆細胞及び非エフェクターｔ細胞、そしてそれらの用途
US20250235482A1 (en) Production and therapeutic use of off-the-shelf double negative t cells
KR102944529B1 (ko) 항-pd-1 항체에 불응성인 nsclc 환자의 치료
JP2024016051A (ja) 末梢血からの末梢血リンパ球（ｐｂｌ）の拡大培養
JP2025156345A (ja) 免疫療法のためのｎｋ細胞組成物および調製物ならびにそれらの製造のための方法
Shi et al. Natural killer cell-based cancer immunotherapy: from basics to clinical trials
JP2022549007A (ja) 養子細胞療法に使用するためのｃｂｌ阻害剤および組成物
JP6073417B2 (ja) 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物
JP2023505102A (ja) ナチュラルキラー細胞を製造する方法およびその組成物
JP2019513836A (ja) 二重特異性抗体を使用して患者の造血幹細胞／造血前駆細胞（ｈｓｃ／ｈｐ）を除去する方法
Van Caeneghem et al. Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities
Baron et al. Clinical manufacturing of regulatory T cell products for adoptive cell therapy and strategies to improve therapeutic efficacy
Moustaki et al. Effect of the simultaneous administration of glucocorticoids and IL-15 on human NK cell phenotype, proliferation and function
Maeda Immune reconstitution after T-cell replete HLA haploidentical hematopoietic stem cell transplantation using high-dose post-transplant cyclophosphamide
JP2022515144A5 (https=)
Rassek et al. New player in CAR-T manufacture field: comparison of umbilical cord to peripheral blood strategies
Deng et al. Prospects and limitations of NK cell adoptive therapy in clinical applications
JP2023505192A (ja) 養子細胞療法としての遺伝子操作された二重陰性ｔ細胞
Caruso et al. NK cells as adoptive cellular therapy for hematological malignancies: advantages and hurdles

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221212

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240313

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250403